FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. Described is a group of inventions comprising a tetraspecific antibody monomer having binding specificity with CD3, EGFR vIII, PD-L1 and 4-1BB, tetraspecific antibody having binding specificity with CD3, EGFR vIII, PD-L1 and 4-1BB, a pharmaceutical composition for treating cancer having a cell expressing EGFR vIII and a method of treating cancer having a cell expressing EGFR vIII in a human.
EFFECT: invention extends the range of agents tetraspecifically binding to CD3, EGFR vIII, PD-L1 and 4-1BB.
9 cl, 13 dwg, 8 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| METHODS OF PRODUCING AND USING GUIDE AND NAVIGATION CONTROL PROTEINS | 2019 |
|
RU2824896C2 |
| ANTI-ROR1/ANTI-CD3 BISPECIFIC BINDING MOLECULES | 2020 |
|
RU2831608C2 |
| COMPOSITIONS OF ANTIBODIES AGAINST ROR1 AND CORRESPONDING METHODS | 2017 |
|
RU2766190C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| THERAPEUTIC COMPOUNDS AND METHODS | 2016 |
|
RU2770001C2 |
